Somers KD - Search Results

1

Serum protein profiles to identify head and neck cancer.

Wadsworth JT, Somers KD, Cazares LH, Malik G, Adam BL, Stack BC Jr, Wright GL Jr, Semmes OJ. Wadsworth JT, et al. Among authors: somers kd. Clin Cancer Res. 2004 Mar 1;10(5):1625-32. doi: 10.1158/1078-0432.ccr-0297-3. Clin Cancer Res. 2004. PMID: 15014013

2

Identification of patients with head and neck cancer using serum protein profiles.

Wadsworth JT, Somers KD, Stack BC Jr, Cazares L, Malik G, Adam BL, Wright GL Jr, Semmes OJ. Wadsworth JT, et al. Among authors: somers kd. Arch Otolaryngol Head Neck Surg. 2004 Jan;130(1):98-104. doi: 10.1001/archotol.130.1.98. Arch Otolaryngol Head Neck Surg. 2004. PMID: 14732777

3

Flt3-ligand induces transient tumor regression in an ectopic treatment model of major histocompatibility complex-negative prostate cancer.

Ciavarra RP, Somers KD, Brown RR, Glass WF, Consolvo PJ, Wright GL, Schellhammer PF. Ciavarra RP, et al. Among authors: somers kd. Cancer Res. 2000 Apr 15;60(8):2081-4. Cancer Res. 2000. PMID: 10786663

4

Inhibition of head and neck squamous cell carcinoma growth and invasion by the calcium influx inhibitor carboxyamido-triazole.

Wu Y, Palad AJ, Wasilenko WJ, Blackmore PF, Pincus WA, Schechter GL, Spoonster JR, Kohn EC, Somers KD. Wu Y, et al. Among authors: somers kd. Clin Cancer Res. 1997 Nov;3(11):1915-21. Clin Cancer Res. 1997. PMID: 9815580

5

Orthotopic treatment model of prostate cancer and metastasis in the immunocompetent mouse: efficacy of flt3 ligand immunotherapy.

Somers KD, Brown RR, Holterman DA, Yousefieh N, Glass WF, Wright GL Jr, Schellhammer PF, Qian J, Ciavarra RP. Somers KD, et al. Int J Cancer. 2003 Dec 10;107(5):773-80. doi: 10.1002/ijc.11464. Int J Cancer. 2003. PMID: 14566827 Free article.

6

Phenotypic and cytogenetic characterization of a cell line derived from primary prostatic carcinoma.

Brothman AR, Lesho LJ, Somers KD, Wright GL Jr, Merchant DJ. Brothman AR, et al. Among authors: somers kd. Int J Cancer. 1989 Nov 15;44(5):898-903. doi: 10.1002/ijc.2910440525. Int J Cancer. 1989. PMID: 2583869

7

Overexpression of p53 in prostate carcinoma is associated with improved overall survival but not predictive of response to radiotherapy.

Incognito LS, Cazares LH, Schellhammer PF, Kuban DA, Van Dyk EO, Moriarty RP, Wright GL Jr, Somers KD. Incognito LS, et al. Among authors: somers kd. Int J Oncol. 2000 Oct;17(4):761-9. doi: 10.3892/ijo.17.4.761. Int J Oncol. 2000. PMID: 10995889

8

Impact of the tumor microenvironment on host infiltrating cells and the efficacy of flt3-ligand combination immunotherapy evaluated in a treatment model of mouse prostate cancer.

Ciavarra RP, Brown RR, Holterman DA, Garrett M, Glass WF 2nd, Wright GL Jr, Schellhammer PF, Somers KD. Ciavarra RP, et al. Among authors: somers kd. Cancer Immunol Immunother. 2003 Sep;52(9):535-45. doi: 10.1007/s00262-003-0383-x. Cancer Immunol Immunother. 2003. PMID: 14627125 Free PMC article.

9

Frequent p53 mutations in head and neck cancer.

Somers KD, Merrick MA, Lopez ME, Incognito LS, Schechter GL, Casey G. Somers KD, et al. Cancer Res. 1992 Nov 1;52(21):5997-6000. Cancer Res. 1992. PMID: 1394225

10

Effects of the calcium influx inhibitor carboxyamido-triazole on the proliferation and invasiveness of human prostate tumor cell lines.

Wasilenko WJ, Palad AJ, Somers KD, Blackmore PF, Kohn EC, Rhim JS, Wright GL Jr, Schellhammer PF. Wasilenko WJ, et al. Among authors: somers kd. Int J Cancer. 1996 Oct 9;68(2):259-64. doi: 10.1002/(SICI)1097-0215(19961009)68:2<259::AID-IJC20>3.0.CO;2-4. Int J Cancer. 1996. PMID: 8900438 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

67 results

Search Page